Latest News for: miv

Edit

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff ...

Nasdaq Globe Newswire 15 Dec 2025
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026� ... .
Edit

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (Form 8-K) (Kyverna Therapeutics Inc)

Public Technologies 15 Dec 2025
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome ... Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed.
Edit

Medivir's partner Vetbiolix announces publication of Landmark Proof-of-Concept Clinical Study Results for VBX-1000 (MIV-701) (Medivir AB)

Public Technologies 28 Nov 2025
2025-11-28 10.00.00 CET Medivir AB - Investor News Medivir's partner Vetbiolix announces publication of Landmark Proof-of-Concept Clinical Study Results for VBX-1000 (MIV-701) ... MIV-701 is another ...
Edit

FDA grants Medivir´s MIV-711 Orphan Drug Designation for the treatment of Osteogenesis Imperfecta

Pharmiweb 27 Nov 2025
We are delighted that MIV-711 has been granted ODD by the FDA, which strengthens the evidence base for its ability to positively impact bone remodeling and its potential to treat bone-related disorders”, said Jens Lindberg, CEO of Medivir.
Edit

FDA grants Medivir´s MIV-711 Orphan Drug Designation for the treatment of Osteogenesis Imperfecta (Medivir AB)

Public Technologies 27 Nov 2025
2025-11-27 11.40.00 CET Medivir AB - Investor News FDA grants Medivir´s MIV-711 Orphan Drug Designation for the treatment of Osteogenesis Imperfecta ... We are delighted that MIV-711 has ... About MIV-711.
  • 1

Article Search

tools
×
×
×
×